Retrophin, Inc. (RTRX) Rating Lowered to Strong Sell at Zacks Investment Research
Retrophin, Inc. (NASDAQ:RTRX) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Tuesday.
According to Zacks, “Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company’s approved products include Chenodal®, Cholbam, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego. “
A number of other analysts have also issued reports on RTRX. ValuEngine raised Retrophin from a “sell” rating to a “hold” rating in a report on Friday, August 4th. BidaskClub raised Retrophin from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 24th. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $44.00 target price on shares of Retrophin in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $36.00.
Retrophin (NASDAQ RTRX) opened at $21.09 on Tuesday. The company has a current ratio of 3.88, a quick ratio of 3.83 and a debt-to-equity ratio of 0.15. Retrophin has a fifty-two week low of $15.55 and a fifty-two week high of $26.44.
Retrophin (NASDAQ:RTRX) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.21). The business had revenue of $40.34 million during the quarter, compared to analyst estimates of $40.51 million. Retrophin had a negative net margin of 33.79% and a negative return on equity of 10.13%. The business’s quarterly revenue was up 18.8% compared to the same quarter last year. During the same period last year, the business earned ($0.09) EPS. equities analysts anticipate that Retrophin will post -1.25 earnings per share for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Trexquant Investment LP acquired a new stake in Retrophin in the 3rd quarter valued at approximately $203,000. SG Americas Securities LLC grew its holdings in Retrophin by 1.8% in the 2nd quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock valued at $158,000 after buying an additional 146 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Retrophin in the 3rd quarter valued at approximately $212,000. Legal & General Group Plc grew its holdings in Retrophin by 4.3% in the 2nd quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock valued at $168,000 after buying an additional 355 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of Retrophin in the 3rd quarter worth approximately $249,000.
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.